ReviewOncogene2013
MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.
Review in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 260 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
260 citing papers in PubMed, 1 synthesis or guideline pooled it, 446 citations in OpenAlex.
- Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.Frontiers in immunology · 2021Pooled it
- Trial
- Prognostic and therapeutic importance of TROP-2 and MUC-1 in non-small cell lung cancer: A systematic review and meta-analysis.Biomedical reports · 2026Article
- Stage-Specific Mucin Reprogramming Across the Gastric Cancer Cascade: Unveiling Molecular Mechanisms and Novel Therapeutic Vulnerabilities.Biomolecules · 2026Review
- Translational selenium nanoparticles trigger apoptosis in triple-negative breast cancer cells through the MAPKs/Bcl2 pathway.Bioactive materials · 2026Article
- The Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia.Biomedicines · 2026Review
- Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses.Signal transduction and targeted therapy · 2026Review
- Advances and challenges in CAR-T cell therapy for breast cancer: from molecular design to clinical application.Cancer causes & control : CCC · 2026Review
- MicNet: integrating spatially resolved transcriptomes and pathology images by contrastive deep neural network.Genome biology · 2026Article
- Inhibition of endocytosis by glycans arises from steric rather than electrostatic repulsion.Biophysical journal · 2026Article
- GCNT3 and ST3GAL1 expression correlates with HER2 status and MUC1/β-catenin/Cyclin D1 axis in breast cancer.BMC cancer · 2026Article
- Tumour-Associated MUC1 Exerts Multiple Effects on Cholesterol and Lipid Metabolism-A Potential Pathogenic Effector of Atherosclerosis in Cancer.International journal of molecular sciences · 2026Article
- The Overexpression of Myelin and Lymphocyte Protein (MAL) Downregulates MUC1 and Enhances Cisplatin Sensitivity in Non-Small Cell Lung Cancer Cells.Journal of Cancer · 2026Article
- Immune checkpoint inhibition in breast cancer: targeting PD-1/PD-L1 pathway for therapeutic advances.Breast cancer (Tokyo, Japan) · 2026Review
- Knockout of Mucin 1 inhibits the proliferation, migration, and invasion of human MDA-MB-231 cells by blocking autophagy flow.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- The Anticancer Effect of Kaempferol Through Downregulation of CDKs and PD-L1 in Triple-Negative Breast Cancer Cells.Cancers · 2025Article
- β-Hydroxybutyrate promotes chemoresistance and proliferation in breast cancer cells.Biochemistry and biophysics reports · 2025Article
- In silico design of a multi-epitope vaccine against the triple negative breast cancer.Scientific reports · 2025Article
- Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.Cancers · 2025Review
- Unveiling tissue heterogeneity through genomic interaction-encoded image representation of RNA-sequencing data.American journal of human genetics · 2025Article
200 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Mucin 1 (MUC1) is a heterodimeric protein formed by two subunits that is aberrantly overexpressed in human breast cancer and other cancers. Historically, much of the early work on MUC1 focused on the shed mucin subunit. However, more recent studies have been directed at the transmembrane MUC1-C-terminal subunit (MUC1-C) that functions as an oncoprotein. MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor tyrosine kinases at the cell membrane and contributes to activation of the PI3KAKT and mitogen-activated protein kinase kinase (MEK)extracellular signal-regulated kinase (ERK) pathways. MUC1-C also localizes to the nucleus where it activates the Wnt/β-catenin, signal transducer and activator of transcription (STAT) and NF (nuclear factor)-κB RelA pathways. These findings and the demonstration that MUC1-C is a druggable target have provided the experimental basis for designing agents that block MUC1-C function. Notably, inhibitors of the MUC1-C subunit have been developed that directly block its oncogenic function and induce death of breast cancer cells in vitro and in xenograft models. On the basis of these findings, a first-in-class MUC1-C inhibitor has entered phase I evaluation as a potential agent for the treatment of patients with breast cancers who express this oncoprotein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.